Published in J Nucl Med on June 28, 2012
Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging (2014) 1.04
Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Sci (2014) 0.88
The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts. PLoS One (2014) 0.87
Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging (2013) 0.86
(18)F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with (18)F-FDG and (11)C-Methionine PET. Eur J Nucl Med Mol Imaging (2016) 0.83
Study of LAT1 Expression in Brain Metastases: Towards a Better Understanding of the Results of Positron Emission Tomography Using Amino Acid Tracers. PLoS One (2016) 0.82
Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med (2014) 0.80
Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer. Br J Cancer (2014) 0.80
Imaging tumor metabolism using positron emission tomography. Cancer J (2015) 0.78
Cancer stratification by molecular imaging. Int J Mol Sci (2015) 0.78
Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci (2015) 0.77
Using Metabolomic Profiles as Biomarkers for Insulin Resistance in Childhood Obesity: A Systematic Review. J Diabetes Res (2016) 0.77
Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis. Eur J Nucl Med Mol Imaging (2013) 0.77
Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging. Cancer Sci (2016) 0.76
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin (2016) 0.76
Advantages of L-3-[(18)F] fluoro-alpha-methyl tyrosine over 2-[(18)F]-fluoro-2-deoxyglucose in detecting liver metastasis during positron emission tomography scan. Springerplus (2016) 0.75
Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET. EJNMMI Res (2017) 0.75
Differentiation of malignant tumours from granulomas by using dynamic [(18)F]-fluoro-L-α-methyltyrosine positron emission tomography. EJNMMI Res (2015) 0.75
Effect of α-Methyl versus α-Hydrogen Substitution on Brain Availability and Tumor Imaging Properties of Heptanoic [F-18]Fluoroalkyl Amino Acids for Positron Emission Tomography (PET). J Med Chem (2016) 0.75
Synthesis and biological evaluation of O-[3-18F-fluoropropyl]-α-methyl tyrosine in mesothelioma-bearing rodents. Biomed Res Int (2013) 0.75
Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature (2002) 5.62
Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest (2004) 4.04
CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch (2003) 2.69
Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med (2004) 2.55
Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med (2009) 2.25
Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet (2008) 2.21
Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem (2008) 2.09
New insights into renal transport of urate. Curr Opin Rheumatol (2007) 2.07
Which is the better prognostic factor for resected non-small cell lung cancer: the number of metastatic lymph nodes or the currently used nodal stage classification? J Thorac Oncol (2011) 2.03
Lower lip reconstruction using a combined technique of the webster and johanson methods. Ann Plast Surg (2013) 2.01
The SLC22 drug transporter family. Pflugers Arch (2003) 1.95
Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol (2004) 1.87
Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg (2004) 1.87
Relationship of echocardiographic dyssynchrony to long-term survival after cardiac resynchronization therapy. Circulation (2010) 1.87
Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology (2008) 1.86
Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol (2006) 1.83
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther (2011) 1.74
Manipulating phospholipids for crystallization of a membrane transport protein. Proc Natl Acad Sci U S A (2006) 1.71
Molecular physiology of urate transport. Physiology (Bethesda) (2005) 1.69
Transport of 99mTc-MAG3 via rat renal organic anion transporter 1. J Nucl Med (2004) 1.66
The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer (2005) 1.64
MR imaging in the evaluation of chronic or recurrent headache. Radiology (2005) 1.64
Primary thymic mucosa-associated lymphoid tissue lymphoma: diagnostic tips. J Thorac Oncol (2010) 1.61
Gamma-protocadherins are targeted to subsets of synapses and intracellular organelles in neurons. J Neurosci (2003) 1.61
TGF-beta superfamily members modulate growth, branching, shaping, and patterning of the ureteric bud. Dev Biol (2004) 1.59
Activity-induced protocadherin arcadlin regulates dendritic spine number by triggering N-cadherin endocytosis via TAO2beta and p38 MAP kinases. Neuron (2007) 1.58
L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer (2006) 1.57
Usefulness of echocardiographic dyssynchrony in patients with borderline QRS duration to assist with selection for cardiac resynchronization therapy. JACC Cardiovasc Imaging (2010) 1.57
L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int (2009) 1.57
Branching morphogenesis and kidney disease. Development (2004) 1.54
Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci (2004) 1.52
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer (2007) 1.48
Adult kidney tubular cell population showing phenotypic plasticity, tubulogenic capacity, and integration capability into developing kidney. J Am Soc Nephrol (2005) 1.46
The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer (2013) 1.46
High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes. J Surg Oncol (2010) 1.46
Myocardial contractile function in the region of the left ventricular pacing lead predicts the response to cardiac resynchronization therapy assessed by two-dimensional speckle tracking echocardiography. J Am Soc Echocardiogr (2010) 1.45
Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat Genet (2004) 1.45
Molecular physiology of renal organic anion transporters. Am J Physiol Renal Physiol (2006) 1.44
Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol (2002) 1.44
Non-clustered protocadherin. Cell Adh Migr (2011) 1.44
Echocardiographic assessment of myocardial strain. J Am Coll Cardiol (2011) 1.43
Cadherin activity is required for activity-induced spine remodeling. J Cell Biol (2004) 1.43
Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition. Am J Physiol Renal Physiol (2004) 1.43
Endothelial lipase modulates pressure overload-induced heart failure through alternative pathway for fatty acid uptake. Hypertension (2013) 1.42
Temporally distinct demands for classic cadherins in synapse formation and maturation. Mol Cell Neurosci (2004) 1.42
Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest (2007) 1.41
A novel role of the C-terminus of b 0,+ AT in the ER-Golgi trafficking of the rBAT-b 0,+ AT heterodimeric amino acid transporter. Biochem J (2009) 1.41
Correction of late post-traumatic enophthalmos using a tissue expander. Ann Plast Surg (2006) 1.40
The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. J Biol Chem (2004) 1.40
Outcomes of ultrasound-guided foam sclerotherapy for varicose veins of the lower extremities: a single center experience. Dermatol Surg (2011) 1.39
l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci (2008) 1.37
The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med (2013) 1.36
Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report. J Neurosurg (2007) 1.36
Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem (2003) 1.34
Organic anion transporter family: current knowledge. J Pharmacol Sci (2006) 1.34
Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol (2005) 1.33
Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol (2002) 1.32
Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther (2002) 1.31
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci (2011) 1.30
Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol (2012) 1.29
Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep (2013) 1.28
Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer (2002) 1.28
Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol (2005) 1.27
Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol (2010) 1.27
Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther (2003) 1.25
Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data. Acad Radiol (2004) 1.25
A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese. Kidney Int (2004) 1.24
Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells. J Physiol (2012) 1.23
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer (2007) 1.23
Maternal protein restriction in the rat inhibits placental insulin, mTOR, and STAT3 signaling and down-regulates placental amino acid transporters. Endocrinology (2011) 1.23